JNK Inhibitor VA JNK1, JNK2, and JNK3 inhibitor

JNK Inhibitor V (CAS 345987-15-7)

JNK Inhibitor V | CAS 345987-15-7 is rated 5.0 out of 5 by 1.
  • y_2019, m_11, d_19, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.3-b1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202672, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 59ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile
Application: A JNK1, JNK2, and JNK3 inhibitor
CAS Number: 345987-15-7
Purity: >95%
Molecular Weight: 372.45
Molecular Formula: C20H16N6S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

JNK Inhibitor V is a potent and cell permeable ATP competitive JNK inhibitor (hJNK1: IC50 = 150nM, hJNK2: IC50 = 220nM and hJNK3: IC50 = 70 nM). Experiments have reported JNK signaling pathway to play a role in ischemia-induced cell death in hippocampal CA1 neurons in a gerbil model. Therefore, preventing the activation of JNK has the potential of being neuroprotective. Additionally, in murine studies, the compound has been observed to reduce infarct size caused by myocardial ischemia. JNK Inhibitor V has also been noted to display anti-inflammatory capacities.


References

1. Ferrandi, C., et al. 2004. Br. J. Pharmacol. 142: 953-960. PMID: 15210584
2. Carboni, S., et al. 2004. J. Pharmacol. Exp. Ther. 310: 25-32. PMID: 14988419
3. Gaillard, P., et al. 2005. J. Med. Chem. 48: 4596-4607. PMID: 15999997

Physical State :
Solid
Solubility :
Soluble in DMSO (10mg/ml)
Storage :
Desiccate at -20° C
Melting Point :
242.22° C (Predicted)
Boiling Point :
614.71° C at 760 mmHg (Predicted)
Density :
1.37 g/cm3 (Predicted)
Refractive Index :
n20D 1.72 (Predicted)
IC50 :
hJNK 1: IC50 = 150 nM; hJNK 2: IC50 = 220 nM; hJNK 3: IC50 = 70 nM; Serine/threonine-protein kinase PIM3: IC50 = 30 nM (human); Glycogen synthase kinase-3 beta: IC50 = 40 nM (human); Dual-specificity tyrosine-phosphorylation regulated kinase 2: IC50 = 300 nM (human)
pK Values :
pKb: 5.32
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
11422035
SMILES :
C1=CC=C2C(=C1)N/C(=C(/C#N)\\C3=NC(=NC=C3)NCCC4=CN=CC=C4)/S2

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

JNK Inhibitor V  Product Citations

See how others have used JNK Inhibitor V. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 23382840  Lamy, E. et al. 2013. PloS one. 8: e53240.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 115ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Wu Wu, J. et al. (PubMed 26362062) used the JNK Inhibitor V to demonstrate that activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells. -SCBT Publication Review
Date published: 2015-06-06
  • y_2019, m_11, d_19, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.3-b1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202672, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 48ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.